JP2017522311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522311A5 JP2017522311A5 JP2017502120A JP2017502120A JP2017522311A5 JP 2017522311 A5 JP2017522311 A5 JP 2017522311A5 JP 2017502120 A JP2017502120 A JP 2017502120A JP 2017502120 A JP2017502120 A JP 2017502120A JP 2017522311 A5 JP2017522311 A5 JP 2017522311A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- agent
- therapy
- tigit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 60
- 239000002246 antineoplastic agent Substances 0.000 claims 55
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 51
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 51
- 239000003795 chemical substances by application Substances 0.000 claims 41
- 230000000694 effects Effects 0.000 claims 40
- 230000002401 inhibitory effect Effects 0.000 claims 35
- 206010028980 Neoplasm Diseases 0.000 claims 32
- 239000000427 antigen Substances 0.000 claims 29
- 108091007433 antigens Proteins 0.000 claims 29
- 102000036639 antigens Human genes 0.000 claims 29
- 239000012634 fragment Substances 0.000 claims 29
- 201000011510 cancer Diseases 0.000 claims 27
- 239000005557 antagonist Substances 0.000 claims 24
- 238000011319 anticancer therapy Methods 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims 16
- -1 anthracycline Substances 0.000 claims 15
- 239000000556 agonist Substances 0.000 claims 13
- 238000002560 therapeutic procedure Methods 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 10
- 238000011282 treatment Methods 0.000 claims 10
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 claims 8
- 102100029740 Poliovirus receptor Human genes 0.000 claims 8
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 230000008685 targeting Effects 0.000 claims 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 7
- 230000003993 interaction Effects 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 108090000978 Interleukin-4 Proteins 0.000 claims 6
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 6
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 6
- 229940022399 cancer vaccine Drugs 0.000 claims 6
- 238000009566 cancer vaccine Methods 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000003966 growth inhibitor Substances 0.000 claims 6
- 229940023041 peptide vaccine Drugs 0.000 claims 6
- 238000002626 targeted therapy Methods 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 claims 5
- 102100025390 Integrin beta-2 Human genes 0.000 claims 5
- 102000013462 Interleukin-12 Human genes 0.000 claims 5
- 108010065805 Interleukin-12 Proteins 0.000 claims 5
- 102100035487 Nectin-3 Human genes 0.000 claims 5
- 230000007423 decrease Effects 0.000 claims 5
- 230000036737 immune function Effects 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 230000036039 immunity Effects 0.000 claims 5
- 230000001965 increasing effect Effects 0.000 claims 5
- 230000004068 intracellular signaling Effects 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 4
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 4
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 4
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 4
- 102100032937 CD40 ligand Human genes 0.000 claims 4
- 102100020997 Fractalkine Human genes 0.000 claims 4
- 108700010013 HMGB1 Proteins 0.000 claims 4
- 101150021904 HMGB1 gene Proteins 0.000 claims 4
- 102100037907 High mobility group protein B1 Human genes 0.000 claims 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 4
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 4
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 4
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims 4
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 4
- 102000000589 Interleukin-1 Human genes 0.000 claims 4
- 102000003814 Interleukin-10 Human genes 0.000 claims 4
- 108090000174 Interleukin-10 Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 108010002616 Interleukin-5 Proteins 0.000 claims 4
- 102000000743 Interleukin-5 Human genes 0.000 claims 4
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 238000009098 adjuvant therapy Methods 0.000 claims 4
- 239000000611 antibody drug conjugate Substances 0.000 claims 4
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 4
- 238000010322 bone marrow transplantation Methods 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 4
- 238000001415 gene therapy Methods 0.000 claims 4
- 238000009169 immunotherapy Methods 0.000 claims 4
- 229940124302 mTOR inhibitor Drugs 0.000 claims 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 4
- 238000002625 monoclonal antibody therapy Methods 0.000 claims 4
- 238000009099 neoadjuvant therapy Methods 0.000 claims 4
- 229960002087 pertuzumab Drugs 0.000 claims 4
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 238000001959 radiotherapy Methods 0.000 claims 4
- 229950008684 sibrotuzumab Drugs 0.000 claims 4
- 150000003384 small molecules Chemical class 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 102100032912 CD44 antigen Human genes 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 3
- 108010074328 Interferon-gamma Proteins 0.000 claims 3
- 102100033467 L-selectin Human genes 0.000 claims 3
- 101150065403 NECTIN2 gene Proteins 0.000 claims 3
- 102100035488 Nectin-2 Human genes 0.000 claims 3
- 229940119182 Selectin agonist Drugs 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical group N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 2
- 229940126638 Akt inhibitor Drugs 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims 2
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 2
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 2
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 101100396524 Capsicum annuum eIF4E gene Proteins 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 102100031506 Complement C5 Human genes 0.000 claims 2
- 108010028773 Complement C5 Proteins 0.000 claims 2
- 229940122558 EGFR antagonist Drugs 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 229930189413 Esperamicin Natural products 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 2
- 101710088083 Glomulin Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 101710123134 Ice-binding protein Proteins 0.000 claims 2
- 101710082837 Ice-structuring protein Proteins 0.000 claims 2
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 2
- 108010041012 Integrin alpha4 Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 102000013691 Interleukin-17 Human genes 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 229940123830 K-Ras inhibitor Drugs 0.000 claims 2
- 229940123917 Lipid kinase inhibitor Drugs 0.000 claims 2
- 229940124647 MEK inhibitor Drugs 0.000 claims 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 2
- 108010008707 Mucin-1 Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 2
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 claims 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 108010090763 Shiga Toxin 2 Proteins 0.000 claims 2
- 108091005735 TGF-beta receptors Proteins 0.000 claims 2
- 101710183280 Topoisomerase Proteins 0.000 claims 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 2
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000002280 anti-androgenic effect Effects 0.000 claims 2
- 229940124650 anti-cancer therapies Drugs 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940044684 anti-microtubule agent Drugs 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 239000000051 antiandrogen Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940125644 antibody drug Drugs 0.000 claims 2
- 239000013059 antihormonal agent Substances 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 229950003145 apolizumab Drugs 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 229950001863 bapineuzumab Drugs 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 2
- 229930195731 calicheamicin Natural products 0.000 claims 2
- 229950006754 cedelizumab Drugs 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 230000001461 cytolytic effect Effects 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 229950009760 epratuzumab Drugs 0.000 claims 2
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 claims 2
- 201000005884 exanthem Diseases 0.000 claims 2
- 229950004923 fontolizumab Drugs 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 229950000518 labetuzumab Drugs 0.000 claims 2
- 229950002950 lintuzumab Drugs 0.000 claims 2
- 229950008001 matuzumab Drugs 0.000 claims 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 2
- 229960005108 mepolizumab Drugs 0.000 claims 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 2
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
- 229960001521 motavizumab Drugs 0.000 claims 2
- 229940035036 multi-peptide vaccine Drugs 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 229960005027 natalizumab Drugs 0.000 claims 2
- 229950010203 nimotuzumab Drugs 0.000 claims 2
- 229950005751 ocrelizumab Drugs 0.000 claims 2
- 229960000470 omalizumab Drugs 0.000 claims 2
- 229960000402 palivizumab Drugs 0.000 claims 2
- 229960001972 panitumumab Drugs 0.000 claims 2
- 229940031734 peptide cancer vaccine Drugs 0.000 claims 2
- 229950003203 pexelizumab Drugs 0.000 claims 2
- 239000003207 proteasome inhibitor Substances 0.000 claims 2
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 2
- 239000003909 protein kinase inhibitor Substances 0.000 claims 2
- 229960003876 ranibizumab Drugs 0.000 claims 2
- 206010037844 rash Diseases 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 229950006551 sontuzumab Drugs 0.000 claims 2
- 229960003989 tocilizumab Drugs 0.000 claims 2
- 229960005267 tositumomab Drugs 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 1
- 101000633107 Homo sapiens Transient receptor potential cation channel subfamily V member 3 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 108090000184 Selectins Proteins 0.000 claims 1
- 102000003800 Selectins Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102000003567 TRPV4 Human genes 0.000 claims 1
- 101150098315 TRPV4 gene Proteins 0.000 claims 1
- 238000012338 Therapeutic targeting Methods 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 102100029605 Transient receptor potential cation channel subfamily V member 3 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000002981 blocking agent Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000002596 immunotoxin Substances 0.000 claims 1
- 229940051026 immunotoxin Drugs 0.000 claims 1
- 230000002637 immunotoxin Effects 0.000 claims 1
- 231100000608 immunotoxin Toxicity 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims 1
- 229960005558 mertansine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000009377 thymus cancer Diseases 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 claims 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229950004362 urtoxazumab Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 229950004393 visilizumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025394P | 2014-07-16 | 2014-07-16 | |
| US62/025,394 | 2014-07-16 | ||
| PCT/US2015/040770 WO2016011264A1 (en) | 2014-07-16 | 2015-07-16 | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020103978A Division JP2020180127A (ja) | 2014-07-16 | 2020-06-16 | Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017522311A JP2017522311A (ja) | 2017-08-10 |
| JP2017522311A5 true JP2017522311A5 (https=) | 2018-08-30 |
Family
ID=55079055
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502120A Withdrawn JP2017522311A (ja) | 2014-07-16 | 2015-07-16 | Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法 |
| JP2020103978A Pending JP2020180127A (ja) | 2014-07-16 | 2020-06-16 | Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法 |
| JP2021198263A Withdrawn JP2022046494A (ja) | 2014-07-16 | 2021-12-07 | Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法 |
| JP2024026145A Pending JP2024075568A (ja) | 2014-07-16 | 2024-02-26 | Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020103978A Pending JP2020180127A (ja) | 2014-07-16 | 2020-06-16 | Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法 |
| JP2021198263A Withdrawn JP2022046494A (ja) | 2014-07-16 | 2021-12-07 | Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法 |
| JP2024026145A Pending JP2024075568A (ja) | 2014-07-16 | 2024-02-26 | Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (9) | US20170143825A1 (https=) |
| EP (1) | EP3169363A4 (https=) |
| JP (4) | JP2017522311A (https=) |
| KR (1) | KR20170023081A (https=) |
| CN (1) | CN107073108A (https=) |
| AU (1) | AU2015289621A1 (https=) |
| BR (1) | BR112017000703A2 (https=) |
| CA (1) | CA2953245A1 (https=) |
| CL (1) | CL2017000080A1 (https=) |
| CO (1) | CO2017001493A2 (https=) |
| CR (1) | CR20170014A (https=) |
| EA (1) | EA201790195A1 (https=) |
| IL (1) | IL249658A0 (https=) |
| MA (1) | MA40437A (https=) |
| MX (1) | MX2016017288A (https=) |
| PE (1) | PE20170140A1 (https=) |
| PH (1) | PH12017500070A1 (https=) |
| SG (2) | SG11201700258VA (https=) |
| WO (1) | WO2016011264A1 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5401001B2 (ja) | 2002-09-11 | 2014-01-29 | ジェネンテック， インコーポレイテッド | 免疫関連疾患の治療のための新規組成物と方法 |
| SG10202112838YA (en) | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| BR112016000853A2 (pt) | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
| MD4733C1 (ro) | 2014-08-19 | 2021-07-31 | Merck Sharp & Dohme Corp | Anticorpi anti-TIGIT |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| DK3653221T5 (da) | 2015-02-19 | 2024-08-26 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| CN108290936B (zh) | 2015-08-14 | 2022-07-12 | 默沙东公司 | 抗tigit抗体 |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| PE20181046A1 (es) | 2015-09-25 | 2018-07-03 | Genentech Inc | Anticuerpos anti-tigit y metodos de uso |
| US10537633B2 (en) * | 2016-03-04 | 2020-01-21 | Jn Biosciences Llc | Antibodies to TIGIT |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| IL317989A (en) | 2016-08-17 | 2025-02-01 | Compugen Ltd | Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof |
| MX2019006072A (es) * | 2016-11-30 | 2019-08-14 | Oncomed Pharm Inc | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). |
| WO2018102746A1 (en) * | 2016-12-02 | 2018-06-07 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to tigit |
| US20200101108A1 (en) * | 2017-03-31 | 2020-04-02 | The Board Of Trustees Of The Le-Land Standford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| JP7348072B2 (ja) | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | 三重併用抗体療法 |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| TWI877769B (zh) * | 2017-12-30 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| AU2019207296A1 (en) * | 2018-01-15 | 2020-07-16 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against TIGIT |
| KR102224556B1 (ko) | 2018-02-06 | 2021-03-09 | 아이-맵 바이오파마 유에스 리미티드 | Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용 |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| US10752691B2 (en) | 2018-03-13 | 2020-08-25 | Tusk Therapeutics Ltd. | Anti-CD25 antibody agents |
| CN120943884A (zh) | 2018-03-27 | 2025-11-14 | 百时美施贵宝公司 | 使用紫外线信号实时监测滴度 |
| SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| MA52289A (fr) | 2018-04-18 | 2021-02-24 | Xencor Inc | Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations |
| MX2021000745A (es) | 2018-07-20 | 2021-03-26 | Surface Oncology Inc | Composiciones anti-cd112r y metodos. |
| JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| AU2019355971B2 (en) | 2018-10-03 | 2025-05-08 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
| AU2019359475A1 (en) | 2018-10-12 | 2021-05-20 | Xencor, Inc. | PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| WO2020176748A1 (en) * | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
| IL286482B2 (en) * | 2019-03-21 | 2025-01-01 | Gamida Cell Ltd | Cultured NK cell fractions for use in combination therapy |
| KR20220012292A (ko) | 2019-05-23 | 2022-02-03 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 배양 배지를 모니터링하는 방법 |
| TWI760751B (zh) | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
| CN112300279A (zh) * | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| US11851466B2 (en) | 2019-10-03 | 2023-12-26 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CN114728171A (zh) | 2019-11-05 | 2022-07-08 | 默克专利有限公司 | 抗tigit抗体及其应用 |
| US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| CN112409450B (zh) * | 2020-03-29 | 2023-01-24 | 郑州大学 | TIGIT-IgV的亲和剂及其应用 |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| MX2022015157A (es) | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Anticuerpos para tigit. |
| KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| CN116406369A (zh) | 2020-10-05 | 2023-07-07 | 百时美施贵宝公司 | 用于浓缩蛋白质的方法 |
| WO2022111612A1 (zh) * | 2020-11-26 | 2022-06-02 | 信达生物制药(苏州)有限公司 | 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途 |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| CN114149489B (zh) * | 2021-11-18 | 2023-12-15 | 厦门大学 | 一种靶向tigit的放射性标记化合物及其制备方法和应用 |
| JP2025509274A (ja) | 2022-03-09 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | 治療用タンパク質の一過性発現 |
| WO2023198060A1 (zh) * | 2022-04-12 | 2023-10-19 | 正大天晴药业集团股份有限公司 | 蛋白酶体抑制剂与抗pd-1抗体的药物组合 |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| EP4658687A1 (en) | 2023-01-31 | 2025-12-10 | University of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| CN120826478A (zh) | 2023-03-06 | 2025-10-21 | 基因泰克公司 | 用于非小细胞肺癌的预后和治疗方法 |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2158318A2 (en) * | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| SG10202112838YA (en) * | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| EP3508215A3 (en) * | 2012-12-03 | 2019-10-02 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| HK1210964A1 (en) * | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
-
2015
- 2015-07-16 EP EP15822079.8A patent/EP3169363A4/en not_active Withdrawn
- 2015-07-16 BR BR112017000703A patent/BR112017000703A2/pt not_active IP Right Cessation
- 2015-07-16 CN CN201580036081.3A patent/CN107073108A/zh active Pending
- 2015-07-16 WO PCT/US2015/040770 patent/WO2016011264A1/en not_active Ceased
- 2015-07-16 PE PE2017000058A patent/PE20170140A1/es unknown
- 2015-07-16 MX MX2016017288A patent/MX2016017288A/es unknown
- 2015-07-16 AU AU2015289621A patent/AU2015289621A1/en not_active Abandoned
- 2015-07-16 SG SG11201700258VA patent/SG11201700258VA/en unknown
- 2015-07-16 EA EA201790195A patent/EA201790195A1/ru unknown
- 2015-07-16 CR CR20170014A patent/CR20170014A/es unknown
- 2015-07-16 CA CA2953245A patent/CA2953245A1/en not_active Abandoned
- 2015-07-16 SG SG10201811841UA patent/SG10201811841UA/en unknown
- 2015-07-16 KR KR1020177001261A patent/KR20170023081A/ko not_active Withdrawn
- 2015-07-16 JP JP2017502120A patent/JP2017522311A/ja not_active Withdrawn
- 2015-07-16 MA MA040437A patent/MA40437A/fr unknown
-
2016
- 2016-12-20 IL IL249658A patent/IL249658A0/en unknown
-
2017
- 2017-01-10 US US15/402,662 patent/US20170143825A1/en not_active Abandoned
- 2017-01-10 PH PH12017500070A patent/PH12017500070A1/en unknown
- 2017-01-12 CL CL2017000080A patent/CL2017000080A1/es unknown
- 2017-02-14 CO CONC2017/0001493A patent/CO2017001493A2/es unknown
-
2018
- 2018-02-07 US US15/890,852 patent/US20180169239A1/en not_active Abandoned
-
2020
- 2020-04-08 US US16/843,604 patent/US20200289647A1/en not_active Abandoned
- 2020-06-16 JP JP2020103978A patent/JP2020180127A/ja active Pending
- 2020-12-11 US US17/118,799 patent/US20210113693A1/en not_active Abandoned
-
2021
- 2021-12-07 JP JP2021198263A patent/JP2022046494A/ja not_active Withdrawn
-
2022
- 2022-06-01 US US17/830,065 patent/US20220331426A1/en not_active Abandoned
-
2023
- 2023-01-13 US US18/154,581 patent/US20230226180A1/en not_active Abandoned
- 2023-10-13 US US18/486,230 patent/US20240082396A1/en not_active Abandoned
-
2024
- 2024-02-26 JP JP2024026145A patent/JP2024075568A/ja active Pending
- 2024-06-05 US US18/734,042 patent/US20240307534A1/en not_active Abandoned
- 2024-12-12 US US18/978,156 patent/US20250108111A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522311A5 (https=) | ||
| JP7313493B2 (ja) | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 | |
| JP7324710B2 (ja) | 肺癌の処置のための抗ｐｄ－１抗体 | |
| AU2016268864B2 (en) | Methods of conditioning patients for T cell therapy | |
| Vacchelli et al. | Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy | |
| JP2020534250A5 (https=) | ||
| KR20260046516A (ko) | T 세포 요법을 위한 진단 방법 | |
| Jasinski et al. | Immunotherapy in pediatric B-cell acute lymphoblastic leukemia: advances and ongoing challenges | |
| JP2018522887A (ja) | 免疫チェックポイント阻害剤を使用する癌の処置法 | |
| JP2016528195A5 (https=) | ||
| CN106413751A (zh) | 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合 | |
| US20190336496A1 (en) | Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers | |
| JP2024016200A (ja) | キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用 | |
| CN111615518B (zh) | 阻断emt途径并克服癌干细胞的il8 | |
| JP2018518465A5 (https=) | ||
| TWI828626B (zh) | 併用包含溶血性鏈球菌之菌體的製劑的療法 | |
| JP2021500320A (ja) | 癌の治療のための配合剤 | |
| Cytryn et al. | Biomarker Analysis From a Phase II Study of AgenT-797 (invariant natural killer T cells) with Botensilimab (Fc-enhanced CTLA-4 inhibitor) and Balstilimab (anti-PD-1) in PD-1 Refractory Gastroesophageal Cancer | |
| ES2891990T3 (es) | Anticuerpo que se une específicamente a ERBB3 y su uso | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| Thakur et al. | In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells | |
| Vishwakarma et al. | Novel Immunotherapeutic Approaches for Cancer Therapy | |
| RU2771759C2 (ru) | Антитела против pd-1 для лечения рака легких | |
| CN116194142A (zh) | 通过施用pd-1抑制剂治疗癌症疼痛的方法 | |
| Kiakou et al. | Cancer immunotherapy: A different approach to the treatment of neoplastic disease. |